SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                  FORM 10-QSB



(Mark  One)
[X]      QUARTERLY  REPORT  UNDER  SECTION  13  OR  15(d)
         OF  THE  SECURITIES  EXCHANGE  ACT  OF  1934

                         For the quarterly period ended
                               September 30, 2001

                                       or

[  ]     TRANSITION  REPORT  PURSUANT  TO  SECTION  13  OR
         15(d)  OF  THE  SECURITIES  EXCHANGE  ACT  OF  1934
         For  the  transition  period  from   to

                         Commission file number 0-31387

                              PROTEQUE CORPORATION
             (Exact name of registrant as specified in its charter)

Delaware                                        52-2257547
(State  or other jurisdiction                (I.R.S.  Employer
of incorporation organization)             or  Identification  No.)

                              301 Hunting Horn Lane
                           Vass, North Carolina 28394
               (Address of principal executive offices (zip code)

                                  910/245-3117
              (Registrant's telephone number, including area code)


Indicate  by check mark whether the registrant (1) filed all reports required to
be  filed  by  Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  last 12 months (or for such shorter period that the registrant was required
to  file such reports), and (2) has been subject to such filing requirements for
the  past  90  days.          Yes   X          No

Indicate  the  number  of  shares outstanding of each of the issuer's classes of
common  equity,  as  of  the  latest  practicable  date.

Class                                 Outstanding  at September 30, 2001
Common  Stock, par value $0.0001                  3,760,000

<PAGE>

PART  I  --  FINANCIAL  INFORMATION

ITEM  1.  FINANCIAL  STATEMENTS

                               PROTEQUE CORPORATION
                          (A Development Stage Company)
                                  Balance Sheet
                            As of September 30, 2001
                                  (Unaudited)
<TABLE>
<CAPTION>

                                           ASSETS
<S>                                          <C>
Prepaid  Financing  Costs               $  75,000
Licensing  Agreement                      500,000
                                         ---------
TOTAL  ASSETS                           $ 575,000
                                         =========
LIABILITIES  AND  STOCKHOLDER'S  EQUITY

LIABILITIES

Notes  Payable                          $ 500,000
Accounts  payable                          86,118
Due  to  related  parties                 220,600
                                         ---------
TOTAL  LIABILITIES                        806,718
                                         ---------
STOCKHOLDER'S  DEFICIT
Preferred  Stock,  $.0001  par  value,
 20,000,000  shares  authorized,  none
 issued  and  outstanding                     --

Common  Stock,  $.0001  par  value,
 100,000,000  shares  authorized,
 3,760,000  issued  and  outstanding         376

Additional  paid-in  capital                 535

Deficit  accumulated  during
  development  stage                    (232,253)
                                        ---------
Total                                   (231,342)

Less  stock  subscriptions  receivable      (376)
                                        ---------
Total  Stockholders  Deficit            (231,718)
                                        ---------
TOTAL  LIABILITIES  AND
   STOCKHOLDER'S  EQUITY               $ 575,000
                                       ==========

</TABLE>
   See  accompanying  notes  to  financial  statements

<PAGE>

                             PROTEQUE CORPORATION
                          (A Development Stage Company)
                            Statement of Operations
                                  (Unaudited)

<TABLE>
<CAPTION>

                                                             March  24,  1999
               Three  Months  Ended    Nine  Months  Ended   (Inception)
                 Sept 30,   Sept 30,   Sept 30,  Sept 30,    to June 30,
                    2001      2000      2001       2000      2001
<S>                 <C>       <C>       <C>        <C>        <C>

Income          $  33,710  $   -    $  33,710  $    -      $  33,710

Cost  of  Goods
 Sold               7,135      -        7,135       -          7,135
                ---------  -------   --------   ---------   --------
Gross  Profit      26,575      -       26,575       -         26,575
                ---------  -------   --------   ---------   --------
Expenses
 Organization
  expense              -       -            -       -            535
 General  and
  Administrative 258,253       -      258,253                258,293

                ---------  -------   --------   ---------   --------

Total  expenses  258,253       -      258,253       -        258,828
                ---------  -------   --------   ---------   --------
NET  LOSS      $(231,718)  $   -   $ (231,718)  $   -      $(232,253)
              ===========  ======= ===========  =========  ==========

</TABLE>
     See  accompanying  notes  to  financial  statements

<PAGE>
<TABLE>
<CAPTION>
                              PROTEQUE CORPORATION
                          (A Development Stage Company)
                            Statements of Cash Flows
                                    Unaudited

                                                               March  24,  1999
                                Nine  Months  Ended              (Inception)
                             Sept 30, 2001   Sept 30,2000     To  June  30,2001

<S>                                  <C>             <C>            <C>
CASH  FLOWS  FROM  OPERATING
    ACTIVITIES:
 Net  loss                     $  (231,718)      $   -         $  (232,253)
 Adjustments  to  reconcile
 Net  loss  to  net  cash
 used  in  operating  activities
 Contributed  expenses                  -            -                 535
 Increase  in
  Prepaid  financing  costs        (75,000)          -             (75,000)
  Due  to  related  parties        156,350           -             156,350
  Accounts  payable                150,368           -             150,368
                                -----------     ----------     ---------------
 Net  cash  used  in  operating
  activities                             -           -                   -

CASH  FLOWS  FROM  INVESTING
 ACTIVITIES

 Payment for Licensing Agreement  (500,000)          -            (500,000)
                                 ----------    -----------     ---------------

CASH  FLOWS  FROM  FINANCING  ACTIVITIES:
Proceeds  from  issuance  of
 common  stock                           -           -                 100
Proceeds  from  note  payable      500,000        500,000          500,000
Redemption  of  common  stock         (100)          -                (100)
                                 ----------    -----------      --------------
Net  cash  provided  by  (used  in)
 financing  activities             499,900           -             500,000
                                 ----------     ----------      --------------
DECREASE  IN  CASH  AND  CASH
 EQUIVALENTS                          (100)          -                   -
CASH  AND  CASH  EQUIVALENTS
 BEGINNING  OF  PERIOD                 100         100                   -
                                 ----------     ----------      --------------
CASH  AND  CASH  EQUIVALENTS
  END  OF  PERIOD                  $    -       $  100           $       -
                                 ==========     ==========      ==============
</TABLE>

            See  accompanying  notes  to  financial  statement.
<PAGE>


A.  Organization  and  Business  Operations

The  Company  (a  development  stage  company) (the Company) was incorporated in
Delaware  on  March  24,  1999  as Cassia Acquisition Corporation  to serve as a
vehicle  to  effect  a  merger,  exchange of capital stock, asset acquisition or
other business combination with a domestic or foreign private business.  On July
3,  2001, the Company changed its name to Proteque Corporation.  The Company has
entered  into  a  license  agreement  with  Proteque Holdings, Inc. and Proteque
International, LLC for the exclusive rights to the intellectual property related
to  Proteque  SPS  Skin  Protection  System.  (See  Note  3).

B.  Use  of  Estimates

The  preparation  of  the  financial  statements  requires  management  to  make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and  disclosure of contingent assets and liabilities at the date of
the  financial  statements  and  the  reported  amounts of revenues and expenses
during  the  reporting period. Actual results could differ from those estimates.

C.  Cash  and  Cash  Equivalents

For  purposes  of  the statement of cash flows, the Company considers all highly
liquid  investments  purchased with an original maturity of three months or less
to  be  cash  equivalents.

NOTE  2  STOCKHOLDERS'  DEFICIT

A.  Preferred  Stock

The  Company  is  authorized  to  issue  20,000,000 shares of preferred stock at
$.0001  par  value,  with  such  designations,  voting  and  other  rights  and
preferences  as  may  be determined from time to time by the Board of Directors.

B.  Common  Stock

The  Company is authorized to issue 100,000,000 shares of common stock at $.0001
par  value.  During 1999 the Company issued 1,000,000 shares of its common stock
to  Pierce  Mill Associates, Inc. pursuant to Section 4(2) of the Securities Act
of  1933  for  an  aggregate  consideration  of $100.  In June 2001, the Company
redeemed  the  1,000,000  outstanding  shares at par value, and issued 3,760,000
shares  to  an  affiliate  at  par  value.


<PAGE>

The  Company  has  issued  warrants to Acibar Investments International, Ltd. to
purchase  up  to  400,000  shares of the Companys common stock at prices ranging
from  $.75  per  share to $8.00 per share, exercisable at any time until May 23,
2008.

C.  Additional  Paid-In  Capital

Additional  paid-in  capital  represents  the  fair  value  of  the  amount  of
organization and professional costs incurred by related parties on behalf of the
Company  under  a  business  services  agreement.

NOTE  3  RELATED  PARTY  TRANSACTIONS  AND  AGREEMENTS

License  Agreement

The  Company  has  entered into a license agreement with Proteque Holdings, Inc,
and  Proteque  International,  LLC  for the exclusive rights to the intellectual
property  related  to  Proteque  SPS  Skin  Protection  System.  The cost of the
license was $500,000, which has not been paid and is past due. Revisions to this
license  agreement  are  currently  in  discussion.

Management  Agreement

The Company has entered into a management agreement with Proteque International,
LLC  under which Proteque International, LLC will be the exclusive agent for the
supervision,  direction  and  control of operations, marketing, distribution and
sales of Proteque SPS Skin Protection System.  The agreement will continue until
December 31, 2001, unless terminated earlier by agreement of the parties.  Under
the  terms  of  the  management  agreement, the Company  will reimburse Proteque
International,  LLC  all  documented  expenses.

Amounts  Due  Related  Parties

A  related  party  has  incurred  various  expenses  on  behalf  of the Company,
including  legal  costs,  management  services  and  market  research related to
pharmaceutical  products that may be acquired by the Company, and other matters.
Through  September  30,  2001  the  cost  of  those  expenses is estimated to be
$220,600.


<PAGE>

NOTE  4  POTENTIAL  TARGET  PRODUCTS

The  Company  has  had preliminary discussions with a pharmaceutical company for
the  acquisition  of  several  pharmaceutical  products.  The Company is also in
discussions  with  other companies concerning possible product licenses or other
transactions.  The  Company cannot predict what the results of such negotiations
will  be,  if  any.

ITEM  2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Business  Strategy

The  Company  plans  to  acquire  existing  branded  pharmaceutical products and
increase their sales and earnings through proven leveraging of brand, assets and
channel  market  relationships.  The  Company  intends  to  acquire a variety of
branded prescription products primarily in the following overlapping therapeutic
areas:  dermatology, anti-infective products, anti-inflammatory, wound care, and
immunology/allergy.  The  Company  will  target  pharmaceutical  products  and
pharmaceutical  companies and will seek to acquire the rights to those products.
Target  products  will  generally  be branded products in technologically mature
product segments with high sales volumes and distributed through traditional and
emerging channels.  In order to meet its business strategy, the Company may from
time  to  time  acquire  smaller  pharmaceutical  or  other  companies.

License Agreement with Proteque Holdings, Inc.

The  Company  has  entered into a license agreement with Proteque Holdings, Inc.
and  Proteque  International,  LLC  for  the exclusive marketing, manufacturing,
patents,  know-how  and  other intellectual property rights of Proteque SPS Skin
Protection  System,  an  FDA  over-the-counter  non-steroid  skin  protectant to
prevent  and relieve eczema systems in children, adults, physicians, and nurses.
Under  the  terms  of the license agreement, the Company will pay an initial fee
and annual royalties. The Company intends to continue marketing Proteque SPS and
will  conduct  necessary  clinical research to develop prescription product line
extensions  for  Proteque  SPS.

The  Company  is in receipt of a letter from Proteque International, LLC ("LLC")
dated  October 29, 2001. The letter advised the Company that LLC was prepared to
take  remedial  action  provided  to  it under the License Agreement relative to
certain  required  payments and invited the Company to respond. In response, the
Company  requested  certain  revisions to that agreement intended to resolve the
concerns  of  LLC.  The  parties  are  now  negotiating  those  revisions.

There  are no assurances that the Company will be successful in its negotiations
for  product  acquisitions.  Additionally, the Company's ability to successfully
complete such acquisitions will depend upon the availability of adequate sources
of  funding  for  those  acquisitions.


<PAGE>
Certain  Transactions

On  July  3,  2001,  the  Company  changed  its  name  to  Proteque Corporation.

On  October 1, 2001, Katherine D. Courage resigned as a director of the Company.
On  October  11,  2001  Fred  Brachman resigned as a director and officer of the
Company.

Management

The Company has entered into a management agreement with Proteque International,
LLC to assist with the transactions contemplated by the license agreement and to
ensure  a  continuity  of  the  marketing, distribution and sale of the Product.

The  management  agreement provides that Proteque International, LLC will act as
the  Company's exclusive agent for the supervision, direction and control of the
operation and management of the marketing, distribution and sale of the Product.
The agreement will continue until December 1, 2001, unless terminated earlier by
agreement  of  the  parties.  Proteque  will  be  reimbursed  all  ordinary  and
reasonable  expenses  including  salaries, office expenses, travel, trade shows,
conferences,  production  and  storage  of  inventory  and  other  marketing,
distribution  and  sales  expenses.  The  Company  has  determined  that  such
management  agreement  will  provide  continuity and expertise in the marketing,
distribution  and  sale  of  the  Product.

Capital  Resources

The  Company  currently  has  no  cash  on  hand.

Financing  Agreement

On  June 26, 2001, the board of directors authorized the Company to enter into a
financing agreement with Acibar Investments International, Ltd in the form of an
equity  line of credit in the amount of $20,000,000. Under that agreement Acibar
will  periodically  purchase the common stock of the Company at a price equal to
90%  of  its  market  price  at  the time of purchase. The amount of stock to be
purchased  at  any  time is a function of the market price and trading volume of
the  common  stock.  Purchases  are subject to several conditions, including the
requirement  that  the securities be registered under the Securities Act of 1933
and  that  the  common  stock  is  admitted  to quotation on the Nasdaq SmallCap
Market.


<PAGE>

On  June  26,  2001,  the Company issued three common stock purchase warrants to
Acibar  Investments  International, Ltd. Each of the warrants entitles Acibar to
purchase  400,000  common shares of the Company and each may be exercised at any
time  or  times  until May 23, 2008.  The exercise price of the first warrant is
$0.75  per  share,,  of  the  second  warrant  $4.00 per share, and of the third
warrant  $8.00  per  share.

The  Company  is seeking additional sources of funding.  Management expects that
adequate  funds will  be  available  to  execute the Company's business strategy
during  the  next  twelve months.  However, there can be no assurance that these
additional  sources  of  funding  will  be  available.

           PART  II  --  OTHER  INFORMATION

ITEM  1.  LEGAL  PROCEEDINGS

     There  are  no  legal  proceedings  against  the Company and the Company is
unaware  of  such  proceedings  contemplated  against  it.

ITEM  2.  CHANGES  IN  SECURITIES

     Not  applicable.

ITEM  3.  DEFAULTS  UPON  SENIOR  SECURITIES

     Not  applicable.

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF SECURITY  HOLDERS

     Not  applicable.

ITEM  5.  OTHER  INFORMATION

     Not  applicable.

ITEM  6.  EXHIBITS  AND  REPORTS  ON  FORM  8-K

     (a)     Exhibits
(b)     Reports  on  Form  8-K

     The  Company  filed  a  Form  8-K  on  June  27,  2001.


<PAGE>

                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.

CASSIA  ACQUISITION  CORPORATION

By:  /s/  Douglas  Kinney
     --------------------
        Vice  President

Dated:  November  19,  2001